Date: 2016-05-02
Type of information: Private placement
Company: Acadia Pharmaceuticals (USA - CA)
Investors:
Amount: $300 million
Funding type:
Planned used:
Others: * On January 6, 2016, Acadia Pharmaceuticals announced the pricing of an underwritten public offering of 10,344,827 shares of its common stock, offered at a price to the public of $29.00 per share. The gross proceeds from this offering to Acadia are expected to be approximately $300.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Acadia. Acadia has granted the underwriters a 30-day option to purchase up to an aggregate of 1,551,724 additional shares of common stock. The offering is expected to close on or about January 12, 2016, subject to customary closing conditions. * On January 5, 2016, Acadia Pharmaceuticals announced that it intends to offer and sell, subject to market and other conditions, $300,000,000 of shares of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. BofA Merrill Lynch and J.P. Morgan Securities LLC are acting as the joint book-running managers for the offering. Acadia intends to grant the underwriters a 30-day option to purchase an additional $45,000,000 of shares of its common stock. The shares of common stock described above are being offered by Acadia pursuant to a shelf registration statement filed byAcadia with the Securities and Exchange Commission (SEC) that became automatically effective on March 3, 2014.
Therapeutic area:
